SEARCH

SEARCH BY CITATION

References

  • Abassi Z, Francis B, Wessale J, Ovcharenko E, Winaver J, Hoffman A (2002). Effects of endothelin receptors ET(A) and ET(B) blockade on renal haemodynamics in normal rats and in rats with experimental congestive heart failure. Clin Sci 103: 245248.
  • Achmad TH, Rao GS (1992). Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 189: 9941000.
  • Ahn D, Ge Y, Stricklett PK, Gill P, Taylor D, Hughes AK et al. (2004). Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 114: 504511.
  • Amann K, Simonaviciene A, Medwedewa T, Koch A, Orth S, Gross ML et al. (2001). Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 12: 25722584.
  • Amiri F, Paradis P, Reudelhuber TL, Schiffrin EL (2008). Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. J Hypertens 26: 11021109.
  • Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S (1990). Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348: 730732.
  • Arinami T, Ishikawa M, Inoue A, Yanagisawa M, Masaki T, Yoshida MC et al. (1991). Chromosomal assignments of the human endothelin family genes: the endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2-q13.3. Am J Hum Genet 48: 990996.
  • Attina T, Camidge R, Newby DE, Webb DJ (2005). Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91: 825831.
  • Bacon CR, Cary NR, Davenport AP (1996). Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circulation Res 79: 794801.
  • Barton M (2008). Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 4: 490501.
  • Benigni A, Remuzzi G (1999). Endothelin antagonists. Lancet 353: 133138.
  • Benigni A, Perico N, Gaspari F, Zoja C, Bellizzi M, Gabanelli M et al. (1991). Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 260: 331339.
  • Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T et al. (1993). A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44: 440444.
  • Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G (1998a). Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47: 450456.
  • Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G (1998b). Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 54: 353359.
  • Blank U, Essig M, Scandiuzzi L, Benhamou M, Kanamaru Y (2007). Mast cells and inflammatory kidney disease. Immunol Rev 217: 7995.
  • Boesen EI, Krishnan KR, Pollock JS, Pollock DM (2011). ETA activation mediates angiotensin II-induced infiltration of renal cortical T cells. J Am Soc Nephrol 22: 21872192.
  • Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C (2001). Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37: 490496.
  • Bohle A, Wehrmann M, Bogenschutz O, Batz C, Vogl W, Schmitt H et al. (1992). The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract 188: 908924.
  • Callera GE, Montezano AC, Touyz RM, Zorn TM, Carvalho MH, Fortes ZB et al. (2004). ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats. Hypertension 43: 872879.
  • Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG (1978). The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10: 213218.
  • Chou SY, Porush JG (1995). Renal actions of endothelin-1 and endothelin-3: interactions with the prostaglandin system and nitric oxide. Am J Kidney Dis 26: 116123.
  • Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C et al. (2008). Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol 294: 11851194.
  • Cui P, Tani K, Kitamura H, Okumura Y, Yano M, Inui D et al. (2001). A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic peptide for human neutrophils and monocytes. J Leukoc Biol 70: 306312.
  • Davenport AP, Nunez DJ, Brown MJ (1989). Binding sites for 125I-labelled endothelin-1 in the kidneys: differential distribution in rat, pig and man demonstrated by using quantitative autoradiography. Clin Sci 77: 129131.
  • Denton KM, Shweta A, Finkelstein L, Flower RL, Evans RG (2004). Effect of endothelin-1 on regional kidney blood flow and renal arteriole calibre in rabbits. Clin Exp Pharmacol Physiol 31: 494501.
  • DeNucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD et al. (1988). Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 85: 97979800.
  • Dhaun N, Goddard J, Webb DJ (2006). The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17: 943955.
  • Dhaun N, Pollock DM, Goddard J, Webb DJ (2007). Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 28: 573579.
  • Dhaun N, Lilitkarntakul P, Macintyre IM, Muilwijk E, Johnston NR, Kluth DC et al. (2009). Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol 296: 14771483.
  • Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S et al. (2011). Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57: 772779.
  • Dupuis J, Stewart DJ, Cernacek P, Gosselin G (1996). Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94: 12781284.
  • Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD et al. (1990). Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 172: 17411748.
  • Eid H, de Bold ML, Chen JH, de Bold AJ (1994). Epicardial mesothelial cells synthesize and release endothelin. J Cardiovasc Pharmacol 24: 715720.
  • Evans RG, Madden AC, Oliver JJ, Lewis TV (2001). Effects of ET(A)- and ET(B)-receptor antagonists on regional kidney blood flow, and responses to intravenous endothelin-1, in anaesthetized rabbits. J Hypertens 19: 17891799.
  • Fligny C, Barton M, Tharaux PL (2011). Endothelin and podocyte injury in chronic kidney disease. Contrib Nephrol 172: 120138.
  • Freed MI, Wilson DE, Thompson KA, Harris RZ, Ilson BE, Jorkasky DK (1999). Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone. Clin Pharmacol Ther 65: 473482.
  • Fukuda K, Yanagida T, Okuda S, Tamaki K, Ando T, Fujishima M (1996). Role of endothelin as a mitogen in experimental glomerulonephritis in rats. Kidney Int 49: 13201329.
  • Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M et al. (2009). Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol 297: 14481456.
  • Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M (2000). Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105: 925933.
  • Gasic S, Wagner OF, Vierhapper H, Nowotny P, Waldhausl W (1992). Regional haemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to overall disposal of the peptide. J Cardiovasc Pharmacol 19: 176180.
  • Ge Y, Stricklett PK, Hughes AK, Yanagisawa M, Kohan DE (2005). Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol 289: F692F698.
  • Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y et al. (2006). Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol 291: F1274F1280.
  • Ge Y, Bagnall A, Stricklett PK, Webb D, Kotelevtsev Y, Kohan DE (2008). Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol 295: 16351640.
  • Goddard J, Eckhart C, Johnston NR, Cumming AD, Rankin AJ, Webb DJ (2004a). Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 15: 26012610.
  • Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ et al. (2004b). Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 109: 11861193.
  • Gomez-Garre D, Largo R, Liu XH, Gutierrez S, Lopez-Armada MJ, Palacios I et al. (1996). An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 50: 962972.
  • Greka A, Mundel P (2012). Cell biology and pathology of podocytes. Ann Rev Physiol 74: 299323.
  • Guo JK, Cantley LG (2010). Cellular maintenance and repair of the kidney. Ann Rev Physiol 72: 357376.
  • Gurbanov K, Rubinstein I, Hoffman A, Abassi Z, Better OS, Winaver J (1996). Differential regulation of renal regional blood flow by endothelin-1. Am J Physiol 271: 11661172.
  • Guruli G, Pflug BR, Pecher S, Makarenkova V, Shurin MR, Nelson JB (2004). Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 104: 21072115.
  • Haynes WG, Webb DJ (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344: 852854.
  • Herman WH, Emancipator SN, Rhoten RL, Simonson MS (1998). Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol 275: 817.
  • Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V et al. (1997). Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99: 13801389.
  • Hocher B, Schwarz A, Fagan KA, Thone-Reineke C, El-Hag K, Kusserow H et al. (2000). Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 23: 1926.
  • Hocher B, Schwarz A, Reinbacher D, Jacobi J, Lun A, Priem F et al. (2001). Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87: 161169.
  • Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. (2005). Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45: 198202.
  • Ikeda M, Kohno M, Horio T, Yasunari K, Yokokawa K, Kano H et al. (1995). Effect of thrombin and PDGF on endothelin production in cultured mesangial cells derived from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 22: 197198.
  • Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K et al. (1989). The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 86: 28632867.
  • Inscho EW, Imig JD, Cook AK, Pollock DM (2005). ET(A) and ET(B) receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br J Pharmacol 146: 10191026.
  • Ishizawa K, Yoshizumi M, Tsuchiya K, Houchi H, Minakuchi K, Izawa Y et al. (2004). Dual effects of endothelin-1 (1-31): induction of mesangial cell migration and facilitation of monocyte recruitment through monocyte chemoattractant protein-1 production by mesangial cells. Hypertens Res 27: 433440.
  • Iwasaki S, Homma T, Matsuda Y, Kon V (1995). Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J Biol Chem 270: 69977003.
  • Jaffer FE, Knauss TC, Poptic E, Abboud HE (1990). Endothelin stimulates PDGF secretion in cultured human mesangial cells. Kidney Int 38: 11931198.
  • Juergens UR, Racke K, Uen S, Haag S, Lamyel F, Stober M et al. (2008). Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: new evidence for beneficial anti-inflammatory potency of ETB-receptor antagonism. Pulm Pharmacol Ther 21: 533539.
  • Karet FE, Davenport AP (1996). Localization of endothelin peptides in human kidney. Kidney Int 49: 382387.
  • Kaw S, Hecker M, Vane JR (1992). The two-step conversion of big endothelin 1 to endothelin 1 and degradation of endothelin 1 by subcellular fractions from human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A 89: 68866890.
  • Kelly KJ, Dominguez JH (2010). Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am J Nephrol 32: 469475.
  • Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H et al. (1998). Positionally cloned gene for a novel glomerular protein – nephrin – is mutated in congenital nephrotic syndrome. Mol Cell 1: 575582.
  • Kluth DC (2007). Pro-resolution properties of macrophages in renal injury. Kidney Int 72: 234236.
  • Kobayashi Y, Sakamoto Y, Shibasaki M, Kimura I, Matsuo H (1997). Human alveolar macrophages synthesize endothelins by thrombin. J Immunol 158: 54425447.
  • Kohan DE (1997). Endothelins in the normal and diseased kidney. Am J Kid Dis 29: 226.
  • Kohan DE, Rossi NF, Inscho EW, Pollock DM (2011). Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91: 177.
  • Kuc R, Davenport AP (2004). Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J Cardiovasc Pharmacol 44: 224226.
  • Lehrke I, Waldherr R, Ritz E, Wagner J (2001). Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol 12: 23212329.
  • Mallick NP, Short CD, Hunt LP (1987). How far since Ellis? The Manchester study of glomerular disease. Nephron 46: 113124.
  • Mathieson PW (2012). The podocyte as a target for therapies – new and old. Nat Rev Nephrol 8: 5256.
  • Maurer M, Wedemeyer J, Metz M, Piliponsky AM, Weller K, Chatterjea D et al. (2004). Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432: 512516.
  • Mencarelli M, Pecorelli A, Carbotti P, Valacchi G, Grasso G, Muscettola M (2009). Endothelin receptor A expression in human inflammatory cells. Regul Pept 158: 15.
  • Mishra R, Leahy P, Simonson MS (2003). Gene expression profile of endothelin-1-induced growth in glomerular mesangial cells. Am J Physiol 285: 11091115.
  • Montanari A, Biggi A, Carra N, Fasoli E, Calzolari M, Corsini F et al. (2000). Endothelin-A blockade attenuates systemic and renal hemodynamic effects of L-NAME in humans. Hypertension 35: 518523.
  • Montanari A, Carra N, Perinotto P, Iori V, Fasoli E, Biggi A et al. (2002). Renal hemodynamic control by endothelin and nitric oxide under angiotensin II blockade in man. Hypertension 39: 715720.
  • Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C et al. (2005). In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 166: 13091320.
  • Morigi M, Buelli S, Zanchi C, Longaretti L, Macconi D, Benigni A et al. (2006). Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 169: 19651975.
  • Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T (2006). Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 10841093.
  • Nakano D, Pollock DM (2009). Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension 53: 324330.
  • Odoux C, Crestani B, Lebrun G, Rolland C, Aubin P, Seta N et al. (1997). Endothelin-1 secretion by alveolar macrophages in systemic sclerosis. Am J Respir Crit Care Med 156: 14291435.
  • Opocensky M, Kramer HJ, Backer A, Vernerova Z, Eis V, Cervenka L et al. (2006). Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 48: 965971.
  • Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C et al. (1993). Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 43: 354358.
  • Orth SR, Amann K, Gehlen F, Unger L, Wagner J, Raschack M et al. (2000). Adult human mesangial cells (HMCs) express endothelin-B-receptors which mediate endothelin-1-induced cell growth. J Cardiovasc Pharmacol 36: 232237.
  • Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N et al. (2004). Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 44: 974981.
  • Patrignani P, Del Maschio A, Bazzoni G, Daffonchio L, Hernandez A, Modica R et al. (1991). Inactivation of endothelin by polymorphonuclear leukocyte-derived lytic enzymes. Blood 78: 27152720.
  • Pernow J, Franco-Cereceda A, Matran R, Lundberg JM (1989). Effect of endothelin-1 on regional vascular resistance in the pig. J Cardiovasc Pharmacol 13: 205206.
  • Plato CF, Pollock DM, Garvin JL (2000). Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release. Am J Physiol 279: 326333.
  • Pollock DM (2001). Contrasting pharmacological ETB receptor blockade with genetic ETB deficiency in renal responses to big ET-1. Physiol Genom 6: 3943.
  • Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA (1994). Effects of endothelin-1 on renal function in humans. Implications for physiology and pathophysiology. Kidney Int 46: 376381.
  • Radford MG, Jr, Donadio JV, Jr, Bergstralh EJ, Grande JP (1997). Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8: 199207.
  • Rebibou JM, He CJ, Delarue F, Peraldi MN, Adida C, Rondeau E et al. (1992). Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 7: 288292.
  • Remuzzi G, Bertani T (1998). Pathophysiology of progressive nephropathies. N Engl J Med 339: 14481456.
  • Rubinstein I, Gurbanov K, Hoffman A, Better OS, Winaver J (1995). Differential effect of endothelin-1 on renal regional blood flow: role of nitric oxide. J Cardiovasc Pharmacol 26: S208S210.
  • Ruggenenti P, Perna A, Remuzzi G (2003). Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63: 22542261.
  • Sakamoto H, Sasaki S, Hirata Y, Imai T, Ando K, Ida T et al. (1990). Production of endothelin-1 by rat cultured mesangial cells. Biochem Biophys Res Commun 169: 462468.
  • Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K et al. (1990). Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 348: 732735.
  • Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM (2010). Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 56: 942949.
  • Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM (2011). Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia 54: 979988.
  • Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK et al. (2007). Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18: 143154.
  • Schiffrin EL (2005). Vascular endothelin in hypertension. Vascul Pharmacol 43: 1929.
  • Schmetterer L, Dallinger S, Bobr B, Selenko N, Eichler H-G, Woltz M (1998). Systemic and renal effects of an ETA receptor subtype-specific antagonist in healthy subjects. Br J Pharmacol 124: 930934.
  • Schneider MP, Boesen EI, Pollock DM (2007). Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47: 731759.
  • Simonson MS, Ismail-Beigi F (2011). Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J Biol Chem 286: 1100311008.
  • Simonson MS, Wann S, Mene P, Dubyak GR, Kester M, Nakazato Y et al. (1989). Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 83: 708712.
  • Sorensen SS, Madsen JK, Pedersen EB (1994). Systemic and renal effects of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol 266: 411418.
  • Spath M, Pavenstadt H, Muller C, Petersen J, Wanner C, Schollmeyer P (1995). Regulation of phosphoinositide hydrolysis and cytosolic free calcium induced by endothelin in human glomerular epithelial cells. Nephrol Dial Transplant 10: 12991304.
  • Speciale L, Roda K, Saresella M, Taramelli D, Ferrante P (1998). Different endothelins stimulate cytokine production by peritoneal macrophages and microglial cell line. Immunology 93: 109114.
  • Spirig R, Potapova I, Shaw-Boden J, Tsui J, Rieben R, Shaw SG (2009). TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. Mol Immunol 46: 31783182.
  • Takeda M, Iwasaki S, Hellings SE, Yoshida H, Homma T, Kon V (1994). Divergent expression of Eta and Etb receptors in response to cyclosporine in mesangial cells. Am J Pathol 144: 473479.
  • Tostes RC, Touyz RM, He G, Chen X, Schiffrin EL (2002). Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin Sci 103: 2530.
  • Watson AM, Li J, Schumacher C, de Gasparo M, Feng B, Thomas MC et al. (2010). The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 53: 192203.
  • Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M (1998). Endothelin: new discoveries and rapid progress in the clinic. Trend Pharmacol Sci 19: 58.
  • Welsh GI, Saleem MA (2010). Nephrin-signature molecule of the glomerular podocyte? J Pathol 220: 328337.
  • Wesson DE, Simoni J, Green DF (1998). Reduced extracellular pH increases endothelin-1 secretion by human renal microvascular endothelial cells. J Clin Invest 101: 578583.
  • Wilson SH, Simari RD, Lerman A (2001). The effect of endothelin-1 on nuclear factor kappa B in macrophages. Biochem Biophys Res Commun 286: 968972.
  • Wright CD, Cody WL, Dunbar JB, Jr, Doherty AM, Hingorani GP, Rapundalo ST (1994). Characterization of endothelins as chemoattractants for human neutrophils. Life Sci 55: 16331641.
  • Yamamoto T, Hirohama T, Uemura H (2002). Endothelin B receptor-like immunoreactivity in podocytes of the rat kidney. Arch Histol Cytol 65: 245250.
  • Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S, Kumagaye S et al. (1988a). Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A 85: 69646967.
  • Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. (1988b). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411415.
  • Yoshimoto S, Ishizaki Y, Sasaki T, Murota S (1991). Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 22: 378383.
  • Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, Salio M et al. (2011). Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol 301: 11141123.
  • Zouki C, Baron C, Fournier A, Filep JG (1999). Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(A) receptors and platelet-activating factor. Br J Pharmacol 127: 969979.